Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments

被引：0

作者：

Nieto Barbero, Ma Asuncion ^{[1
]}

Javier Gonzalez-Gamiz, Francisco ^{[1
]}

Jesus Rodriguez-Nieto, Ma ^{[2
]}

Sanchez, Susana ^{[3
]}

Gaudo, Javier ^{[4
]}

Valenzuela, Claudia ^{[5
]}

Lopez-Muniz, Belen ^{[6
]}

Gomez-Carrera, Luis ^{[7
]}

Laporta, Rosalia ^{[8
]}

Casanova, Alvaro ^{[9
]}

Teresa Rio, Maria ^{[10
]}

Neumomadrid, Refipimad ^{[11
]}

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] Fdn Jimenez Diaz, Madrid, Spain

[3] Hosp Univ Principe de Asturias, Alcaa De Henares, Spain

[4] Hosp Univ Ramon y Cajal, Madrid, Spain

[5] Hosp Univ Princesa, Madrid, Spain

[6] Hosp Univ Infanta Leonor, Madrid, Spain

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Puerta de Hierro, Majadahonda, Spain

[9] Hosp Univ Henares, Coslada, Spain

[10] Hosp Univ Getafe, Getafe, Spain

[11] Neumomadrid, Madrid, Spain

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

Idiopathic pulmonary fibrosis; Treatments; Comorbidities;

D O I：

10.1183/13993003.congress-2019.PA1301

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA1301

引用

页数：3

共 50 条

[21] EFFICACY AND SAFETY OF ANTIFIBROTIC AGENTS IN IDIOPATHIC PULMONARY FIBROSIS
Nunez-Garcia, L.
Valenzuela, C.
Alonso, T.
Vicente, E. F.
Ancochea, J.
Castaneda, S.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 759 - 760
[22] Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, Timothy M.
Sangaralingham, Lindsey R.
Yao, Xiaoxi
Sanghavi, Darshak
Shah, Nilay D.
Limper, Andrew H.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (02) : 168 - 174
[23] Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, Toby M.
Strek, Mary E.
RESPIRATORY RESEARCH, 2019, 20 (01)
[24] Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Drakopanagiotakis, Fotios
Roesner, Franziska
Vancheri, Carlo
Bonniaud, Philippe
Wells, Athol
Wagner, Jasmin
Crestani, Bruno
Guenther, Andreas
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[25] The Impact of Comorbidities on Idiopathic Pulmonary Fibrosis Outcomes
Sharif, Roozbeh
Zouk, Aline
Kulkarni, Tejaswini
Acosta, Pilar
Luckhardt, Tracy
Thannickal, Victor
de Andrade, Joao Alberto
CHEST, 2016, 150 (04) : 471A - 471A
[26] Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, Antonella
Lonati, Chiara
Cassandro, Roberto
Elia, Davide
Pelosi, Giuseppe
Torre, Olga
Zompatori, Maurizio
Uslenghi, Elisabetta
Harari, Sergio
EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153):
[27] Nintedanib and Pirfenidone New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions
Raghu, Ganesh
Selman, Moises
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (03) : 252 - 254
[28] Novel Treatments for Idiopathic Pulmonary Fibrosis
Spagnolo, Paolo
AMERICAN JOURNAL OF MEDICINE, 2015, 128 (05): : 447 - 449
[29] New treatments for idiopathic pulmonary fibrosis
Montero-Martinez, C.
ARCHIVOS DE BRONCONEUMOLOGIA, 2006, 42 (01): : 1 - 2
[30] Treatments for Idiopathic Pulmonary Fibrosis Reply
Richeldi, Luca
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (08): : 783 - 783

← 1 2 3 4 5 →